Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF
Status:
Terminated
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if adding brivanib to irinotecan can
help control the disease in patients with colorectal cancer that has spread. The safety of
this drug combination will also be studied.